[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[S. 2750 Introduced in Senate (IS)]
<DOC>
119th CONGRESS
1st Session
S. 2750
To require the Director of the Office of Science and Technology Policy
to establish a Federal regulatory sandbox program for artificial
intelligence, and for other purposes.
_______________________________________________________________________
IN THE SENATE OF THE UNITED STATES
September 10, 2025
Mr. Cruz introduced the following bill; which was read twice and
referred to the Committee on Commerce, Science, and Transportation
_______________________________________________________________________
A BILL
To require the Director of the Office of Science and Technology Policy
to establish a Federal regulatory sandbox program for artificial
intelligence, and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Strengthening Artificial
intelligence Normalization and Diffusion By Oversight and
eXperimentation Act'' or the ``SANDBOX Act''.
SEC. 2. ARTIFICIAL INTELLIGENCE REGULATORY SANDBOX PROGRAM.
The National Science and Technology Policy, Organization, and
Priorities Act of 1976 (42 U.S.C. 6611 et seq.) is amended by adding at
the end the following:
``TITLE VII--ARTIFICIAL INTELLIGENCE REGULATORY SANDBOX PROGRAM
``SEC. 701. DEFINITIONS.
``In this title:
``(1) Agency.--The term `agency' has the meaning given the
term in section 551 of title 5, United States Code.
``(2) Applicable agency.--The term `applicable agency'
means an agency that has jurisdiction over the enforcement or
implementation of a covered provision for which an applicant is
seeking a waiver or modification under the Program.
``(3) Artificial intelligence; artificial intelligence
system.--The terms `artificial intelligence' and `artificial
intelligence system' have the meaning given the term
`artificial intelligence' in section 5002 of the National
Artificial Intelligence Initiative Act of 2020 (15 U.S.C.
9401).
``(4) Artificial intelligence development method.--The term
`artificial intelligence development method' means a business
model or production method that, in whole or in part, uses one
or more artificial intelligence systems.
``(5) Artificial intelligence product or service.--The term
`artificial intelligence product or service' means a product or
service that uses or contains, in whole or in part, one or more
artificial intelligence systems.
``(6) Covered provision.--The term `covered provision' has
the meaning given the term `rule' in section 804(3) of title 5,
United States Code, including any associated guidance,
frequently asked questions publications, bulletins, or
associated, derivative material and any rule the adoption of
which is expressly required by statute.
``(7) Director.--The term `Director' means the Director of
the Office of Science and Technology Policy.
``(8) Health and safety risk.--The term `health and safety
risk' means a risk that is likely to cause--
``(A) bodily harm to a human life (including life
before birth);
``(B) loss of human life (including life before
birth); or
``(C) a substantial adverse effect on the health of
a human (including an unborn human).
``(9) Program.--The term `Program' means the artificial
intelligence regulatory sandbox program established pursuant to
section 702(a).
``(10) Risk of economic damage.--The term `risk of economic
damage' means likely to cause tangible, physical harm to the
property or assets of a consumer.
``(11) Unfair or deceptive trade practice.--The term
`unfair or deceptive trade practice'--
``(A) means an unfair or deceptive act or practice
that is declared unlawful pursuant to section 5 of the
Federal Trade Commission Act (15 U.S.C. 45); or
``(B) has the meaning given such term in--
``(i) the Policy Statement of the Federal
Trade Commission on Deception, issued on
October 14, 1983; or
``(ii) the Policy Statement of the Federal
Trade Commission on Unfairness, issued on
December 17, 1980.
``SEC. 702. ESTABLISHMENT OF ARTIFICIAL INTELLIGENCE REGULATORY SANDBOX
PROGRAM.
``(a) Establishment.--
``(1) In general.--Not later than one year after the date
of the enactment of this Act, the Director shall establish and
operate, in accordance with the requirements of this section,
an artificial intelligence regulatory sandbox program, under
which the Director and persons may apply for a temporary waiver
or modification of one or more covered provisions of an
applicable agency in order to test, experiment, or temporarily
provide to consumers artificial intelligence products or
services or artificial intelligence development methods on a
limited basis without being subject to the enforcement,
licensing, or authorization requirements of such covered
provisions.
``(2) Regulations.--In establishing the Program under
paragraph (1), the Director shall--
``(A) establish an application process for a
temporary waiver or modification described in paragraph
(1), including the creation of a standardized form for
applicants to provide the information required under
subsection (c);
``(B) establish a process by which the Director may
submit an application for a temporary waiver or
modification described in paragraph (1) in accordance
with subsection (c)(3); and
``(C) establish a process for review of
applications submitted pursuant to a process
established under subparagraph (A) or (B) in accordance
with the requirements of this section for assessing
whether an application submitted for the Program
presents a health and safety risk, a risk of economic
damage, or a risk of unfair or deceptive trade
practices, which shall be--
``(i) published in the Federal Register and
made publicly available with a detailed list of
the criteria used to make such assessments; and
``(ii) subject to public comment before
final publication in the Federal Register.
``(b) Purpose.--The purpose of the Program is to incentivize--
``(1) the development of current or new artificial
intelligence products and services and artificial intelligence
development methods;
``(2) the expansion of economic opportunities from
artificial intelligence development;
``(3) the creation of jobs from artificial intelligence
development; and
``(4) the creation of opportunities for artificial
intelligence innovation in the United States.
``(c) Application Process for Waivers and Modifications.--
``(1) In general.--To apply for a waiver or modification
under the Program, an applicant shall, pursuant to the process
established under subsection (a)(2)(A), submit to the Director
an application therefor that includes--
``(A) confirmation that the applicant--
``(i) is subject to the jurisdiction of the
Federal Government; and
``(ii) has established, or plans to
establish not later than 180 days after the
date on which the applicant enters into a
written agreement under subsection (e), a
business that is incorporated or has a
principal place of business in the United
States from which the artificial intelligence
products or services or artificial intelligence
development methods are deployed;
``(B) relevant contact information, including the
legal name, address, telephone number, email address,
and website of the applicant;
``(C) a description of any criminal conviction of
the applicant or any senior management personnel or
director of the business of the applicant; and
``(D) a description of any artificial intelligence
product or service or artificial intelligence
development method to be tested, experimented, or
deployed for which the applicant is requesting a waiver
or modification, and for each such artificial
intelligence product or service or artificial
intelligence development method--
``(i) identification of each covered
provision that the applicant seeks to have
waived or modified during participation in the
Program and the reasons why the waiver or
modification is needed;
``(ii) a description of the manner by which
the product or service or development method
would--
``(I) benefit consumers;
``(II) enhance the operational
efficiency of the business of the
applicant;
``(III) expand economic
opportunities;
``(IV) create jobs; or
``(V) further the innovation or
development of artificial intelligence;
``(iii) an explanation of how potential
benefits of the product or service or
development method outweigh the risks, taking
into account any mitigation measures, which
shall include--
``(I) a description of the
reasonably foreseeable risks associated
with waiving or modifying each covered
provision identified under clause (i)
during participation in the Program,
including any--
``(aa) health and safety
risk;
``(bb) risk of economic
damage; and
``(cc) risk of unfair or
deceptive trade practices;
``(II) the manner in which the
applicant intends to reasonably
mitigate any risk identified pursuant
to subclause (I);
``(iv) the requested time periods for which
the waiver or modification of each covered
provision identified under clause (i) would
apply;
``(v) confirmation that the applicant
understands that the applicant will be subject
to and must comply with all statutes and
regulations after the conclusion of testing,
experimenting, or deploying such product or
service or development method under the
Program; and
``(vi) a list of each agency that may have
jurisdiction, in whole or in part, over the
product or service or development method to be
tested, experimented, or deployed by the
applicant.
``(2) Assistance.--The Director may, upon request, consult
with an applicant and provide assistance completing an
application described in paragraph (1), including by--
``(A) identifying--
``(i) the likely covered provisions that
could be relevant and eligible for a waiver or
modification under the Program; and
``(ii) the agencies with authority over the
covered provisions identified under clause (i);
and
``(B) providing anonymized information on other
relevant applications or aggregate applicant trends.
``(3) Director-submitted application.--The Director may
submit an application to waive or modify any covered provision
under the Program, if in the opinion of the Director the waiver
or modification proposed in the application will advance the
development, deployment, or use of artificial intelligence in
the United States.
``(d) Agency Review.--
``(1) Transmission.--Not later than 14 days after the date
on which the Director receives a completed application under
paragraph (1) of subsection (c) or submits a completed
application under paragraph (3) of that subsection, the
Director shall submit a copy of the application to the head of
each applicable agency.
``(2) Review.--The head of an applicable agency shall
review an application received under paragraph (1) with respect
to the covered provision or provisions under the jurisdiction
of the agency and solicit input, and demonstrate due
consideration of such input, from the private sector and
technical experts with relevance to the Program, on--
``(A) whether the plan of the applicant with
respect to testing, experimenting, or deploying an
artificial intelligence product or service or an
artificial intelligence development method would--
``(i) benefit consumers;
``(ii) enhance the operational efficiency
of the business of the applicant;
``(iii) expand economic opportunities;
``(iv) create jobs; or
``(v) further the innovation or development
of artificial intelligence; and
``(B) whether the potential benefits of the plan
outweigh any--
``(i) health and safety risk;
``(ii) risk of economic damage; and
``(iii) risk of unfair or deceptive trade
practices.
``(3) Method.--The head of an applicable agency may conduct
its review of applications received under paragraph (2) by
establishing advisory boards or working groups to review and
provide input on the applications.
``(4) Agency decision.--
``(A) In general.--Subject to subparagraph (B), the
head of an applicable agency who receives a copy of an
application under paragraph (1) shall, taking into
consideration the recommendations of the advisory board
of the applicable agency, make the agency decision to
grant or deny the application with respect to the
covered provision or provisions requested to be waived
or modified that are under the jurisdiction of the
agency.
``(B) In part approval.--If more than one
applicable agency receives a copy of an application
under paragraph (1)--
``(i) the head of each applicable agency,
with input from the advisory board of the
applicable agency, shall grant or deny the
waiver or modification of each covered
provision over which the applicable agency has
jurisdiction; and
``(ii)(I) if each applicable agency that
receives an application under paragraph (1)
grants the request for a waiver or
modification, the Director shall grant the
entire application; or
``(II) if an applicable agency denies part
of an application and another applicable agency
grants part of the application, the Director
shall approve the application in part and
specify in the decision which covered
provisions are waived or modified.
``(5) Record of agency decision.--
``(A) In general.--Not later than 90 days after
receiving a copy of an application under paragraph (1),
the head of an applicable agency shall approve or deny
the application and submit to the Director a record of
the agency decision.
``(B) Elements.--The record of the agency decision
required by subparagraph (A) to be submitted by the
head of an applicable agency shall include--
``(i) a description of each covered
provision over which the applicable agency has
jurisdiction for enforcement or implementation
that the applicant is seeking to have waived or
modified and a list of the reasonably
foreseeable risks, if any, that could result
from the requested waiver or modification,
including any--
``(I) health and safety risk;
``(II) risk of economic damage; and
``(III) risk of unfair or deceptive
trade practices;
``(ii) if the application is approved, a
description, if applicable, of--
``(I) the manner by which the
applicant will mitigate the risks
identified in clause (i); and
``(II) the manner by which
consumers will be protected during the
term for which the waiver or
modification remains in effect;
``(iii) if the head of the applicable
agency denies the waiver or modification--
``(I) a description of the reasons
for the denial, including--
``(aa) an explanation of
the manner by which a waiver or
modification could cause any of
the risks described in clause
(i); and
``(bb) the likelihood of
such reasonably foreseeable
risks occurring; and
``(II) the reasons why the
application cannot be approved in part
or reformed to mitigate the risks
described under subclause (I)(aa) and
any information the head of the
applicable agency relied on to support
these reasons; and
``(iv) if the head of the applicable agency
would deny the waiver or modification unless
the risks described in clause (i) are
mitigated, a recommendation of the means by
which the applicant can mitigate such risks.
``(C) No record submitted.--If the head of the
applicable agency does not submit a record of the
agency decision by the deadline required by
subparagraph (A), the Director shall presume that the
head of the applicable agency does not object to the
granting of the waiver or modification requested by the
applicant and may proceed with the application.
``(D) Extension.--The head of the applicable agency
may request one 30-day extension of the deadline
required by subparagraph (A) for submission of the
record of the agency decision.
``(E) Expedited review.--If the head of the
applicable agency provides a recommendation described
in subparagraph (B)(iv), the Director shall provide the
applicant 60 days to make necessary changes to the
application, and the applicant may resubmit the
application to the head of the applicable agency for
expedited review of not more than 60 days from the date
of resubmission of the completed application.
``(e) Written Agreement.--
``(1) In general.--If the head of an agency, or the
Director upon an appeal under subsection (g), grants the entire
application or part of the application under subsection (d)(4),
any waiver or modification requested shall not be effective
until the applicant enters into a written agreement with the
Director and the head of the agency that describes--
``(A) each covered provision that is waived or
modified under the Program; and
``(B) the terms the applicant shall abide by to
mitigate any risk described in the record of the agency
decision pursuant to subsection (d)(5)(B)(i).
``(2) Requirement.--Each written agreement entered into
under paragraph (1) shall include a requirement that the
applicant notify the Director and the head of any relevant
applicable agency of any incident that results in harm to the
health and safety of a consumer, economic damage, or an unfair
or deceptive trade practice under the Program not later than 72
hours after the incident occurs.
``(3) Timeline.--The Director shall provide to the
applicant a copy of the written agreement described in
paragraph (1) not later than 45 days after the date on which
the application is granted, in part or in whole, under
subsection (d)(4).
``(f) Publication of Director-Submitted Applications and
Utilization by Applicants.--
``(1) In general.--If the head of an agency, or the
Director upon an appeal under subsection (g), grants a
Director-submitted application, in whole or part, under
subsection (d)(4), the Director shall publish in the Federal
Register notice of any waiver or modification granted and any
information required to be submitted to the Director for an
applicant to utilize such waiver or modification under
paragraph (2).
``(2) Authority.--In the case described in paragraph (1),
any person may submit an application to utilize such waiver or
modification, pursuant to fulfilling the requirements of
subsection (e) and any requirement developed by the Director
under paragraph (3).
``(3) Process for utilization.--The Director may develop a
standardized process for the submission and consideration of an
application to utilize a waiver or modification of a covered
provision granted under paragraph (1).
``(g) Appeals.--
``(1) In general.--If the head of an applicable agency
denies an application under subsection (d)(4), the applicant
may submit to the Director an appeal for reconsideration, or in
the case of a Director-submitted application shall prepare a
statement, which shall--
``(A) address the comments in the record of the
agency decision submitted under subsection (d)(5) that
resulted in denial of the application; and
``(B) include the manner by which the applicant
plans to mitigate the risks identified in the record of
the agency decision.
``(2) Response.--Not later than 60 days after receiving an
appeal under paragraph (1), the Director shall--
``(A) determine whether the appeal sufficiently
addresses the concerns raised in the record of the
agency decision submitted under subsection (d)(5); and
``(B)(i) if the Director determines that the appeal
sufficiently addresses the concerns, file a record of
the agency decision and provide a statement detailing
how the concerns have been mitigated and approve the
application; or
``(ii) if the Director determines that the appeal
does not sufficiently address the concerns, file a
record of the agency decision and provide a statement
detailing how the concerns have not been mitigated and
deny the application.
``(h) Judicial Review.--For purposes of review under section 704 of
title 5, United States Code, the following shall be considered a final
agency action:
``(1) A record of the agency decision submitted under
subsection (d)(5).
``(2) The granting of a request to renew a waiver or
modification under subsection (i)(3)(C).
``(3) The failure of the Director to provide a written
agreement subject to the terms of subsection (e).
``(4) The revocation of a waiver or modifications under
subsection (j).
``(i) Period of Waiver or Modification.--
``(1) Initial period.--Except as provided in this
subsection, a waiver or modification granted under the Program
shall be for a term of 2 years.
``(2) Notification before ending offering.--If a person
decides to end deployment of its artificial intelligence
product, service, or method before the end of the initial
period described in paragraph (1), the person shall, not later
than 30 days before the date on which the person ends
deployment of the product, service, or method, submit to the
Director a report on actions taken by the person to ensure
consumers have not been harmed as a result of the termination
of the product, service, or method.
``(3) Renewal.--
``(A) In general.--The person granted a waiver or
modification under the Program may request for renewal
of the waiver or modification for a maximum of 4
additional 2-year periods.
``(B) Notification.--Not later than 30 days before
the end of an initial period under paragraph (1), a
person that is granted a waiver or modification under
the Program shall notify the Director if the person
intends to seek renewal under subparagraph (A).
``(C) Decision.--The Director shall grant a request
made pursuant to subparagraph (A), unless the Director
determines that--
``(i) relevant information or circumstances
have materially changed since the waiver or
modification was granted and the person must
submit a new or amended application; or
``(ii) the person granted the waiver or
modification is not in compliance with the
terms of the written agreement entered into
pursuant to subsection (e) and the person is
unable to correct the action under subsection
(j)(2).
``(j) Revocation.--If the Director determines that a person that
was granted a waiver or modification under the Program is not in
compliance with the terms of the written agreement entered into
pursuant to subsection (e), the Director--
``(1) shall give the person 30 days to correct the action,
or additional 30-day periods if the Director considers it
appropriate;
``(2) if the person does not correct the action by the end
of the 30-day period, the Director may end the participation of
the person in the Program by revoking the waiver or
modification.
``(k) Terms.--A person for which a waiver or modification is
granted under the Program shall be subject to the following terms:
``(1) No existing right of action of a consumer to seek
actual damages or an equitable remedy may be waived or modified
under the Program.
``(2) While a waiver or modification is in effect, and the
person is in compliance with the written agreement entered into
pursuant to subsection (e), the person shall not be subject to
the criminal or civil enforcement of a covered provision
specifically identified in the waiver or modification.
``(3) An agency may not file or pursue any punitive action
against the person during the period for which the waiver or
modification is in effect, including a civil penalty, fine, or
license suspension or revocation for a violation of a covered
provision identified in the waiver or modification, unless the
person is not in compliance with the written agreement entered
into pursuant to subsection (e).
``(4) The person shall not have immunity related to any
criminal offense that is not expressly identified in the waiver
or modification.
``(5) The Federal Government shall not be responsible for
any business losses if the waiver or modification is revoked at
any time, including any action brought under section 1346(b) or
1491 of title 28, United States Code.
``(6) The person shall notify the Director and the head of
any applicable agency of any incident that results in harm to
the health and safety of a consumer, economic damage, or an
unfair or deceptive trade practice under the Program not later
than 72 hours after the incident occurs.
``(7) The person shall abide by all terms of the written
agreement entered into pursuant to subsection (e).
``(l) Consumer Protection.--Before deploying an artificial
intelligence product or service to consumers under a waiver or
modification granted under the Program, and throughout the period the
waiver or modification remains in effect, a person shall disclose,
through a publicly accessible website or similar public means, the
following to consumers:
``(1) The name and contact information of the person.
``(2) A description of the participation of the person in
the Program, and if applicable, disclosure that the person does
not have a license or other authorization to provide artificial
intelligence products or services under provisions not waived
or modified under the Program.
``(3) If applicable, that the artificial intelligence
product or service is undergoing testing and may not function
as intended and may expose the consumer to certain risks as
identified in the record of the agency decision of the
applicable agency submitted under subsection (d)(5).
``(4) That the person is not immune from existing civil
liability for any loss or damage caused by the artificial
intelligence product or service.
``(5) That the person is not immune from criminal
prosecution for violations of covered provisions that are not
waived or modified under the Program.
``(6) That the artificial intelligence product or service
is a temporary demonstration and may be discontinued at the end
of the initial period under paragraph (1) of subsection (i) or
before the end of the initial period under paragraph (2) of
that subsection.
``(7) The expected commencement date of the initial period
under subsection (i)(1).
``(8) The contact information of the National Artificial
Intelligence Initiative Office and that the consumer may
contact the Initiative Office to file a complaint.
``(m) Record Keeping.--
``(1) In general.--A person who is granted a waiver or
modification under the Program shall retain all records,
documents, and data directly related to the participation of
the person in the Program.
``(2) Request for documents.--Upon request by the Director,
a person granted a waiver or modification under the Program
shall make available for inspection any record, document, or
data retained under paragraph (1).
``(n) Reports.--
``(1) Persons granted a waiver or modification.--
``(A) In general.--Each person who is granted a
waiver or modification under the Program shall submit
to the Director a report that includes--
``(i) if applicable, the number of
consumers participating in or receiving the
artificial intelligence product or service or
the artificial intelligence development method
offered by the person under the Program;
``(ii) an assessment of the likely risks
and the manner by which the person is
mitigating those risks, consistent with the
terms of the written agreement entered into
under subsection (e);
``(iii) an identification of any previously
unanticipated risks that have manifested during
the deployment of the artificial intelligence
product or service or the artificial
intelligence development method;
``(iv) a description of any adverse
incident and any action taken by the person to
repair the harm to consumers; and
``(v) a description of the benefits of the
waiver or modification, including, if
applicable, studies, surveys, financial
benefits, or additional quantitative measures
demonstrating such benefits.
``(B) Timing.--Each person shall submit a report
required under subparagraph (A)--
``(i) 40 days after the commencement of the
period for which a waiver or modification is
granted under the Program;
``(ii) 30 days after the halfway mark of
the period for which a waiver or modification
is granted under the Program; and
``(iii) 30 days before the expiration of--
``(I) the period for which a waiver
or modification is initially granted
under the Program; and
``(II) each 2-year period for which
the waiver or modification is renewed
under subsection (i)(3).
``(2) Annual report to congress.--Not later than 1 year
after the date of the enactment of the Strengthening Artificial
intelligence Normalization and Diffusion By Oversight and
eXperimentation Act, and annually thereafter, the Director
shall submit to Congress a report on the Program, which shall
include, for the 1-year period preceding the submission of the
report--
``(A) the number of applications approved received
and the number of applications approved;
``(B) the name and a description of each applicant
that was granted a waiver or modification under the
Program;
``(C) a description of the benefits to the public
from the Program;
``(D) a description of any harm to the public from
the Program;
``(E) the covered provisions that have been waived
or modified and the number of times such provisions
have been waived or modified;
``(F) the total number of consumers affected by
such waivers or modifications described in subsection
(E); and
``(G) all applicant, Director, and agency materials
related to the Program.
``(o) Coordination With State Artificial Intelligence Programs.--
The Director shall--
``(1) establish mechanisms for sharing information with
State programs that are similar or comparable to the Program;
``(2) coordinate application review processes where
jurisdictions overlap;
``(3) accept joint applications for projects benefitting
from both Federal and State regulatory relief; and
``(4) work to harmonize testing approaches whenever
feasible.
``(p) Rule of Construction.--Nothing in this section shall be
construed--
``(1) to require a person that is granted a waiver or
modification under the Program to publicly disclose proprietary
information, including trade secrets or commercial or financial
information that is privileged or confidential; or
``(2) to affect any other provision of law that is not
included in a waiver or modification provided under the
Program.
``(q) Sunset.--The Program shall terminate on the date that is 12
years after the date on which the Director establishes the Program
under subsection (a).
``SEC. 703. CONGRESSIONAL REVIEW OF COVERED PROVISIONS.
``(a) Joint Resolution of Approval Defined.--In this section, the
term `joint resolution of approval' means only a joint resolution of
either House of Congress--
``(1) the matter after the resolving clause of which
contains only--
``(A) a list of some or all of the covered
provisions that were identified under subsection (b)(1)
in a special message submitted to Congress under that
subsection; and
``(B) a provision that immediately repeals or
adopts amendments to the covered provisions listed
under subparagraph (A) upon enactment of the joint
resolution of approval; and
``(2) upon which Congress completes action before the end
of the first period of 60 legislative days after the date on
which the special message is received by Congress.
``(b) Submission.--
``(1) In general.--Not later than the first day on which
both Houses of Congress are in session after May 1 of each
year, the Director of the Office of Science and Technology
Policy (in this section referred to as the `Director') shall
submit to Congress a special message that details each covered
provision that the Director recommends should be amended or
repealed as a result of persons being able to operate safely
without those covered provisions under the artificial
intelligence regulatory sandbox program established under
section 5107(b).
``(2) Elements.--The special message submitted under
paragraph (1) shall include--
``(A) a list of each covered provision waived or
modified and how many times that provision has been
waived or modified;
``(B) a list of each covered provision that is the
subject of an application for waiver or modification
that has been denied, how many times applications have
been denied, and a summary of the reasons behind such
denial;
``(C) a list of any covered provision that the
Director determines should be repealed, for any reason,
including a brief rationale for the Director's
determination;
``(D) a list of any covered provision that the
Director determines should be amended, including the
recommended textual changes to the covered provision,
including a brief rationale for the Director's
determination; and
``(E) an explanation of why each covered provision
described in subparagraphs (A) and (B) should be
amended or repealed.
``(3) Delivery to house and senate; printing.--Each special
message submitted under paragraph (1) shall be--
``(A) delivered to the Clerk of the House of
Representatives and the Secretary of the Senate; and
``(B) printed in the Congressional Record.
``(c) Approval by Congress.--
``(1) Introduction.--Beginning on the date on which the
Director submits a special message to Congress under subsection
(b)(1), any member of the Senate or House of Representative may
introduce a joint resolution of approval relating to the
special message.
``(2) Consideration in house of representatives.--
``(A) Committee referral.--A joint resolution of
approval introduced in the House of Representatives
shall be referred to the appropriate committee of the
House of Representatives.
``(B) Reporting and discharge.--If the committee to
which a joint resolution of approval has been referred
to has not reported the joint resolution of approval
within 10 legislative days after the date of referral,
the committee shall be discharged from further
consideration of the joint resolution.
``(C) Proceeding to consideration.--Beginning on
the third legislative day after the committee to which
a joint resolution of approval has been referred
reports the joint resolution of approval to the House
or has been discharged from further consideration
thereof, it shall be in order to move to proceed to
consider the joint resolution of approval in the House.
All points of order against the motion are waived. Such
a motion shall not be in order after the House has
disposed of a motion to proceed on the joint resolution
of approval. The previous question shall be considered
as ordered on the motion to its adoption without
intervening motion. The motion shall not be debatable.
A motion to reconsider the vote by which the motion is
disposed of shall not be in order.
``(D) Floor consideration.--The joint resolution of
approval shall be considered as read. All points of
order against the joint resolution of approval and
against its consideration are waived. The previous
question shall be considered as ordered on the joint
resolution of approval to final passage without
intervening motion except 2 hours of debate equally
divided and controlled by the sponsor of the joint
resolution of approval (or a designee) and an opponent.
A motion to reconsider the vote on passage of the joint
resolution of approval shall not be in order.
``(3) Consideration in the senate.--
``(A) Committee referral.--A joint resolution of
approval introduced in the Senate shall be referred to
the appropriate committee of the Senate.
``(B) Reporting and discharge.--If the committee to
which a joint resolution has been referred has not
reported the joint resolution of approval within 10
legislative days after the date of referral of the
joint resolution, the committee shall be discharged
from further consideration of the joint resolution and
the joint resolution shall be placed on the appropriate
calendar.
``(C) Proceeding to consideration.--Notwithstanding
Rule XXII of the Standing Rules of the Senate, it is in
order at any time after the committee to which a joint
resolution has been referred reports a joint resolution
of approval or has been discharged from consideration
of such a joint resolution to move to proceed to the
consideration of the joint resolution of approval. The
motion to proceed is not debatable. The motion is not
subject to a motion to postpone. A motion to reconsider
the vote by which the motion is agreed to or disagreed
to shall not be in order.
``(D) Rulings of the chair on procedure.--Appeals
from the decisions of the Chair relating to the
application of the rules of the Senate to the procedure
relating to a joint resolution of approval shall be
decided by the Senate without debate.
``(4) Rules relating to senate and house of
representatives.--
``(A) Treatment of senate joint resolution of
approval in house.--In the House of Representatives,
the following procedures shall apply to a joint
resolution of approval received from the Senate (unless
the House has already passed a joint resolution
relating to the same proposed action):
``(i) The joint resolution of approval
shall be referred to the appropriate committee
of the House of Representatives.
``(ii) If the committee to which a joint
resolution of approval has been referred has
not reported the joint resolution of approval
within 2 legislative days after the date of
referral, the committee shall be discharged
from further consideration of the joint
resolution.
``(iii) Beginning on the third legislative
day after the committee to which a joint
resolution has been referred reports the joint
resolution of approval to the House or has been
discharged from further consideration thereof,
it shall be in order to move to proceed to
consider the joint resolution of approval in
the House. All points of order against the
motion are waived. Such a motion shall not be
in order after the House has disposed of a
motion to proceed on the joint resolution of
approval. The previous question shall be
considered as ordered on the motion to its
adoption without intervening motion. The motion
shall not be debatable. A motion to reconsider
the vote by which the motion is disposed of
shall not be in order.
``(iv) The joint resolution of approval
shall be considered as read. All points of
order against the joint resolution and against
its consideration are waived. The previous
question shall be considered as ordered on the
joint resolution to final passage without
intervening motion except 2 hours of debate
equally divided and controlled by the sponsor
of the joint resolution of approval (or a
designee) and an opponent. A motion to
reconsider the vote on passage of the joint
resolution of approval shall not be in order.
``(B) Treatment of house joint resolution of
approval in senate.--
``(i) Receipt before passage.--If, before
the passage by the Senate of a joint resolution
of approval, the Senate receives an identical
joint resolution of approval from the House of
Representatives, the following procedures shall
apply:
``(I) That joint resolution of
approval shall not be referred to a
committee.
``(II) With respect to that joint
resolution of approval--
``(aa) the procedure in the
Senate shall be the same as if
no joint resolution had been
received from the House of
Representatives; but
``(bb) the vote on passage
shall be on the joint
resolution from the House of
Representatives.
``(ii) Receipt after passage.--If,
following passage of a joint resolution of
approval in the Senate, the Senate receives an
identical joint resolution of approval from the
House of Representatives, that joint resolution
shall be placed on the appropriate Senate
calendar.
``(iii) No companion measure.--If a joint
resolution of approval is received from the
House, and no companion joint resolution of
approval has been introduced in the Senate, the
Senate procedures under this subsection shall
apply to the House joint resolution of
approval.
``(C) Application to revenue measures.--The
provisions of this paragraph shall not apply in the
House of Representatives to a joint resolution that is
a revenue measure.
``(5) Rules of house of representatives and senate.--This
subsection is enacted by Congress--
``(A) as an exercise of the rulemaking power of the
Senate and the House of Representatives, respectively,
and as such is deemed a part of the rules of each
House, respectively, and supersedes other rules only to
the extent that it is inconsistent with such rules; and
``(B) with full recognition of the constitutional
right of either House to change the rules (so far as
relating to the procedure of that House) at any time,
in the same manner, and to the same extent as in the
case of any other rule of that House.''.
<all>